FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2529823218> ?p ?o ?g. }

• W2529823218 endingPage "2553" @default.
• W2529823218 startingPage "2545" @default.
• W2529823218 abstract "PurposeTo directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical practice.DesignDatabase observational study.ParticipantsTreatment-naïve eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that commenced anti–vascular endothelial growth factor therapy with ranibizumab or aflibercept between December 1, 2013, and January 31, 2015. Eyes were matched at baseline for VA, age, and choroidal neovascular membrane (CNV) size.MethodsLocally weighted scatterplot smoothing curves were used to display VA results. Eyes that switched or discontinued treatment were included with their last observation carried forward.Main Outcome MeasuresChange in mean VA (number of letters read on a logarithm of the minimum angle of resolution chart); number of injections and visits; proportion of eyes with inactive CNV over 12 months.ResultsWe identified 394 eyes (197 treated with ranibizumab and 197 with aflibercept) from 372 patients who received treatment from 34 practitioners. Baseline parameters were well matched. The mean (standard deviation [SD]) VA of ranibizumab-treated eyes increased from 58.6 (20.3) letters at baseline to 62.3 (23.9) (+3.7 [95% confidence interval {CI} 1.4–6.1]) letters (P = 0.001), compared with 58.9 (19.2) letters at baseline to 63.1 (21.5) (+4.26 [95% CI 2.0–6.5]) letters (P < 0.001) for eyes receiving aflibercept. The difference in change in crude VA of 0.6 letters between the 2 groups was not statistically significant (P = 0.76), nor was the difference in adjusted mean VA of the 2 groups (P = 0.26). In completers, the mean (SD) numbers of injections (8.1 [2.1] vs. 8.0 [2.3]; P = 0.27) and visits (9.6 [3.0] vs. 9.5 [3.1]; P = 0.15) did not differ between the 2 groups. The adjusted proportion of eyes in which the CNV lesion was graded as inactive during the study was similar between the eyes receiving ranibizumab and aflibercept (74% vs. 77%, respectively; P = 0.63).ConclusionsVisual acuity outcomes at 12 months did not differ between ranibizumab and aflibercept used for nAMD in this large observational study, nor was a difference in treatment frequency found. To directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical practice. Database observational study. Treatment-naïve eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that commenced anti–vascular endothelial growth factor therapy with ranibizumab or aflibercept between December 1, 2013, and January 31, 2015. Eyes were matched at baseline for VA, age, and choroidal neovascular membrane (CNV) size. Locally weighted scatterplot smoothing curves were used to display VA results. Eyes that switched or discontinued treatment were included with their last observation carried forward. Change in mean VA (number of letters read on a logarithm of the minimum angle of resolution chart); number of injections and visits; proportion of eyes with inactive CNV over 12 months. We identified 394 eyes (197 treated with ranibizumab and 197 with aflibercept) from 372 patients who received treatment from 34 practitioners. Baseline parameters were well matched. The mean (standard deviation [SD]) VA of ranibizumab-treated eyes increased from 58.6 (20.3) letters at baseline to 62.3 (23.9) (+3.7 [95% confidence interval {CI} 1.4–6.1]) letters (P = 0.001), compared with 58.9 (19.2) letters at baseline to 63.1 (21.5) (+4.26 [95% CI 2.0–6.5]) letters (P < 0.001) for eyes receiving aflibercept. The difference in change in crude VA of 0.6 letters between the 2 groups was not statistically significant (P = 0.76), nor was the difference in adjusted mean VA of the 2 groups (P = 0.26). In completers, the mean (SD) numbers of injections (8.1 [2.1] vs. 8.0 [2.3]; P = 0.27) and visits (9.6 [3.0] vs. 9.5 [3.1]; P = 0.15) did not differ between the 2 groups. The adjusted proportion of eyes in which the CNV lesion was graded as inactive during the study was similar between the eyes receiving ranibizumab and aflibercept (74% vs. 77%, respectively; P = 0.63). Visual acuity outcomes at 12 months did not differ between ranibizumab and aflibercept used for nAMD in this large observational study, nor was a difference in treatment frequency found." @default.
• W2529823218 created "2016-10-14" @default.
• W2529823218 creator A5001215128 @default.
• W2529823218 creator A5006941006 @default.
• W2529823218 creator A5019510374 @default.
• W2529823218 creator A5051930478 @default.
• W2529823218 creator A5085397400 @default.
• W2529823218 creator A5088378181 @default.
• W2529823218 date "2016-12-01" @default.
• W2529823218 modified "2023-10-16" @default.
• W2529823218 title "Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study" @default.
• W2529823218 cites W1500728559 @default.
• W2529823218 cites W1964901573 @default.
• W2529823218 cites W1968189763 @default.
• W2529823218 cites W1979601878 @default.
• W2529823218 cites W1980632047 @default.
• W2529823218 cites W1980725734 @default.
• W2529823218 cites W1987641364 @default.
• W2529823218 cites W1992527753 @default.
• W2529823218 cites W1993228662 @default.
• W2529823218 cites W1996649465 @default.
• W2529823218 cites W2001953460 @default.
• W2529823218 cites W2003324689 @default.
• W2529823218 cites W2004117352 @default.
• W2529823218 cites W2009964074 @default.
• W2529823218 cites W2015993450 @default.
• W2529823218 cites W2030856137 @default.
• W2529823218 cites W2051869883 @default.
• W2529823218 cites W2055822421 @default.
• W2529823218 cites W2057628931 @default.
• W2529823218 cites W2085712747 @default.
• W2529823218 cites W2088291107 @default.
• W2529823218 cites W2093044616 @default.
• W2529823218 cites W2112069706 @default.
• W2529823218 cites W2124415048 @default.
• W2529823218 cites W2125587232 @default.
• W2529823218 cites W2134161293 @default.
• W2529823218 cites W2139839585 @default.
• W2529823218 cites W2142629810 @default.
• W2529823218 cites W2143426016 @default.
• W2529823218 cites W2155163959 @default.
• W2529823218 cites W2186681554 @default.
• W2529823218 cites W2299415664 @default.
• W2529823218 cites W2319983832 @default.
• W2529823218 cites W4250031098 @default.
• W2529823218 cites W4361738959 @default.
• W2529823218 cites W633153563 @default.
• W2529823218 doi "https://doi.org/10.1016/j.ophtha.2016.08.016" @default.
• W2529823218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27707549" @default.
• W2529823218 hasPublicationYear "2016" @default.
• W2529823218 type Work @default.
• W2529823218 sameAs 2529823218 @default.
• W2529823218 citedByCount "56" @default.
• W2529823218 countsByYear W25298232182017 @default.
• W2529823218 countsByYear W25298232182018 @default.
• W2529823218 countsByYear W25298232182019 @default.
• W2529823218 countsByYear W25298232182020 @default.
• W2529823218 countsByYear W25298232182021 @default.
• W2529823218 countsByYear W25298232182022 @default.
• W2529823218 countsByYear W25298232182023 @default.
• W2529823218 crossrefType "journal-article" @default.
• W2529823218 hasAuthorship W2529823218A5001215128 @default.
• W2529823218 hasAuthorship W2529823218A5006941006 @default.
• W2529823218 hasAuthorship W2529823218A5019510374 @default.
• W2529823218 hasAuthorship W2529823218A5051930478 @default.
• W2529823218 hasAuthorship W2529823218A5085397400 @default.
• W2529823218 hasAuthorship W2529823218A5088378181 @default.
• W2529823218 hasBestOaLocation W25298232181 @default.
• W2529823218 hasConcept C118487528 @default.
• W2529823218 hasConcept C126322002 @default.
• W2529823218 hasConcept C141071460 @default.
• W2529823218 hasConcept C2776403814 @default.
• W2529823218 hasConcept C2776694085 @default.
• W2529823218 hasConcept C2777802072 @default.
• W2529823218 hasConcept C2778257484 @default.
• W2529823218 hasConcept C2778749236 @default.
• W2529823218 hasConcept C2781100027 @default.
• W2529823218 hasConcept C44249647 @default.
• W2529823218 hasConcept C71924100 @default.
• W2529823218 hasConceptScore W2529823218C118487528 @default.
• W2529823218 hasConceptScore W2529823218C126322002 @default.
• W2529823218 hasConceptScore W2529823218C141071460 @default.
• W2529823218 hasConceptScore W2529823218C2776403814 @default.
• W2529823218 hasConceptScore W2529823218C2776694085 @default.
• W2529823218 hasConceptScore W2529823218C2777802072 @default.
• W2529823218 hasConceptScore W2529823218C2778257484 @default.
• W2529823218 hasConceptScore W2529823218C2778749236 @default.
• W2529823218 hasConceptScore W2529823218C2781100027 @default.
• W2529823218 hasConceptScore W2529823218C44249647 @default.
• W2529823218 hasConceptScore W2529823218C71924100 @default.
• W2529823218 hasIssue "12" @default.
• W2529823218 hasLocation W25298232181 @default.
• W2529823218 hasLocation W25298232182 @default.
• W2529823218 hasOpenAccess W2529823218 @default.
• W2529823218 hasPrimaryLocation W25298232181 @default.
• W2529823218 hasRelatedWork W2015993450 @default.
• W2529823218 hasRelatedWork W2319930158 @default.
• W2529823218 hasRelatedWork W2320987231 @default.

• next